Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
A once-weekly growth hormone shot keeps kids growing. Data from the REAL8 and REAL9 trials show that somapacitan-beco (Sogroya) sustained meaningful increases in height velocity for up to 2 years in children born small for gestational age — whether they were new to GH therapy or switching from a daily regimen. And caregivers overwhelmingly preferred the weekly option.
A once-weekly growth hormone shot keeps kids growing — and families happy
New data from the REAL8 and REAL9 trials show that somapacitan-beco (Sogroya, Novo Nordisk) sustained meaningful growth improvements for up to 2 years in children born small for gestational age (SGA) who failed to achieve catch-up growth. The findings, published in The Journal of Clinical Endocrinology & Metabolism, support the FDA's recently expanded indication for the once-weekly therapy in this population.
In REAL8, children on somapacitan-beco maintained annualized height velocity well above baseline at 2 years, and over 84% of those on the drug for the full trial period reached a normal height range. In the smaller REAL9 trial, treatment-naive children saw height velocity jump from 4.6 to 11.3 cm/year after just 26 weeks. Safety profiles were favorable across both studies, with adverse events largely mild and unrelated to the drug.
By the Numbers
Why it matters: Reducing a daily injection burden to once weekly is a significant quality-of-life improvement for pediatric patients and their families. With strong efficacy, a clean safety profile, and overwhelming caregiver preference for the weekly regimen, somapacitan-beco could meaningfully improve adherence and outcomes for children with SGA-related short stature.
